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Background: Recent evidence has accumulated that MicroRNA (miRNA) dysregulation occurs in the majority of
human malignancies including acute myeloid leukemia (AML) and may contribute to onco-/leukemo-genesis.
Methods: The expression levels of miR-370 and FoxM1 were assessed in 48 newly diagnosed AML patients, 40 AML
patients in 1st complete remission (CR) and 21 healthy controls. Quantitative real-time PCR, western blots, colony
formation assay, and β-Galactosidase ( SA-β-Gal) staining were used to characterize the changes induced by
overexpression or inhibition of miR-370 or FoxM1.
Results: We found that the down-regulation of miR-370 expression was a frequent event in both leukemia cell
lines and primary leukemic cells from patients with de novo AML. Lower levels of miR-370 expression were found
in 37 of 48 leukemic samples from AML patients compared to those in bone marrow cells derived from healthy
adult individuals. Ectopic expression of miR-370 in HL60 and K562 cells led to cell growth arrest and senescence. In
contrast, depletion of miR-370 expression using RNA interference enhanced the proliferation of those leukemic
cells. Mechanistically, miR-370 targets the transcription factor FoxM1, a well established oncogenic factor promoting
cell cycle progression. Moreover, when HL60 and K562 cells were treated with 5-aza-20-deoxycytidine, a DNA
methylation inhibitor, miR-370 expression was up-regulated, which indicates epigenetic silencing of miR-370 in
leukemic cells.
Conclusions: Taken together, miR-370 may function as a tumor suppressor by targeting FoxM1, and the epigenetic
silence of miR-370 thus leads to derepression of FoxM1 expression and consequently contributes to AML
development and progression.
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Acute myeloid leukemia (AML) is a heterogeneous
group of neoplastic haematopoietic diseases character-
ized by proliferation and maturation arrest of myeloid
blasts in bone marrow and blood [1]. The long-term
overall survival (OS) rate for AML patients under the
age of 60 years and 60 years or older is 30–40% and
under 10%, respectively [2], which remains a challenge.
Thus, it is urgently needed to search for new targets for
molecularly designed therapies.* Correspondence: chency@sdu.edu.cn
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reproduction in any medium, provided the ormicroRNAs (miRNAs), small (~22 nucleotide), single-
stranded noncoding RNAs, are a novel class of biological
molecules. Their genes may either give rise to single
miRNAs, or contain several miRNAs in one transcrip-
tional unit as miRNA clusters [3]. miRNAs post-
transcriptionally repress gene expression by recognizing
complementary target sites in the 30untranslated region
(UTR) of target mRNAs [4,5]. miRNAs have been impli-
cated in a large variety of biological processes, including
cell cycle progression, apoptosis, differentiation and
haematopoiesis [6-10], and thereby play important roles
in many pathological processes, including malignant
transformation [11,12]. More than 50% of miRNA genes
are located in cancer-associated genomic regions or in
fragile sites, and both oncogenic and tumor suppressivehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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NAs [13]. Moreover, miRNAs have emerged as critical
regulators of hematopoiesis and their aberrant expres-
sion has been associated with the pathogenesis of
leukemia [14]. Functional validation of deregulated miR-
NAs in hematopoeisis has been shown for several miR-
NAs [15]. Distinctive patterns of increased expression
and/or silencing of multiple miRNAs have been asso-
ciated with specific cytogenetic and molecular subsets of
AML [16]. miR-370 has been noted to be down-
regulated in papillary thyroid carcinoma, colorectal can-
cer [17] and malignant cholangiocytes [18], but evidence
of a biological role for this miRNA in AML has not been
reported. In the present study, we sought to define the
role of miR-370 in AML by investigating its expression
and biological function in leukemic cell lines and blast
cells from patients with de novo AML.
Results
Down-regulation of miR-370 expression in BM blasts from
de novo AML patients
We analyzed miR-370 expression in BM samples from
48 de novo AML patients at diagnosis time using qRT-
PCR. As shown in Figure 1A, the miR-370 level in
patients’ samples was significantly reduced (P < 0.01,
t test) compared to that from healthy controls, while fol-
lowing acquisition of CR in the induction chemotherapy,
miR-370 expression level restored to 0.82 fold of con-
trols. There was no association between the presence of
mature miR-370 and age, gender, blast percentage or
FAB subtypes (data not shown). In six patients, BM sam-
ples were available both at diagnosis time prior toFigure 1 Downexpression of miR-370 in de novo AML patients. (A) m
patients of 1st CR and 21 healthy controls. (B) Restoration of miR-370 expre
induction chemotherapy. The results are shown as miRNA expression aftertreatment and after a complete remission and we found
a lower miR-370 level at diagnosis while at least 2.1-fold
increase in miR-370 expression after CR (Figure 1B).
Changes in proliferation and cellular senescence of
leukemic cells mediated by altered miR-370 expression
We then explored the biological function of miR-370 in
leukemic cells. Cells were transfected with precursors to
miR-370 and miR-370 inhibitor to enhance and decrease
mature miR-370 expression, respectively. Transfection
with the miR-370 precursor increased mature miR-370
expression 114.5 ± 5.70: 1 ± 0.12 (p < 0.05) and 59.8 ±
6.90: 1 ± 0.24 (p < 0.05) (pSilencer-miR vs pSilencer)
times higher in HL60 and K562 cells, respectively
(Figure 2A). Overexpression of miR-370 decreased cell
proliferation (Figure 2C and Additional file 1) (pSilencer
vs pSilencer-miR: HL60: 88 ± 15 vs 11 ± 4, p < 0.01;
K562: 49 ± 5 vs 18 ± 5, p < 0.01). On the other hand,
transfection with the miR-370 inhibitor suppressed mature
miR-370 expression to 31% ± 0.04 (p < 0.05) and 58% ±
0.05 (p < 0.05) lower in HL60 and K562 cells, respectively
(Figure 2B). The decline in miR-370 expression was
coupled with enhanced cell proliferation (Figure 2C) (pSu-
per vs pSuper-miR-inhibitor: HL60: 56 ± 7 vs 72 ± 6, p <
0.05; K562: 66 ± 12 vs 93 ± 7, p < 0.05).
The above result suggests that miR-370 suppresses
proliferation of HL60 and K562 cells. We further wanted
to define the mechanism behind miR-370 overexpres-
sion-mediated proliferation inhibition. We suspected
that miR-370 might trigger cellular senescence program.
Senescence-associated β-Gal staining, a specific marker
for senescent cells [19], was thus performed. A positiveiR-370 expression by qRT-PCR in 48 de novo AML patients, 40 AML
ssion in six patients after complete remission achievement in
normalization with U6 and -ΔCt calculations.
Figure 2 (See legend on next page.)
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fected with miR-370 precursors (Figure 2D) [pSilencer
vs pSilencer-miR (% of β-Gal-positive cells): HL60: 3 ± 1
vs 28 ± 3, p < 0.01; K562: 8 ± 3 vs 40 ± 1, p < 0.01;].Up-regulation of miR-370 expression mediated
by 5-Aza-CdR
DNA methylation is an epigenetic modification that reg-
ulates gene expression. Aberrant DNA methylation has
(See figure on previous page.)
Figure 2 Suppression of AML cell proliferation and induction of cell senescence by overexpression of miR-370 in vitro while
anti-miR-370 expression increases cellular ability of proliferation. (A) miR-370 expression in AML cell lines and its overexpression using a
specific miR-expressing pSilencer vector. The cells were transfected with either miR-370 precursors or with control precursor and harvested after
48 hours. qRT-PCR was applied to detect mature miR-370 level. (B) The depletion of miR-370 expression by a specific miR-370-inhibiting pSuper
plasmid. The method was similar as above. (C) Alterations in foci formation after different treatments in AML cells. The cells were first treated as
above and the efficiently changed miR-370 expression was verified in (A) and (B). For clonogenic assays, 5,000 cells/well (in 6-well plates) were
incubated for 14 days and the foci number was counted. (D) Senescence onset of miR-370-overexpressed AML cells. β-Gal staining was
performed and % of positive cells was calculated.
Zhang et al. Molecular Cancer 2012, 11:56 Page 4 of 11
http://www.molecular-cancer.com/content/11/1/56been implicated in many cancers [20]. Global hypo-
methylation or aberrant hypermethylation of gene pro-
moter CpG islands result, respectively, in tumor cell
genomic instability and gene silencing, particularly of
tumor suppressor genes [17]. Interestingly, the chromo-
somal location of miR-370 on chromosome 14q32.31
has been shown to be regulated by DNA methylation, or
deleted by loss of heterozygosity [14,21] or by hyper-
methylation of an CpG island 200 bp upstream in the
mother allele [22]. Treatment with 5 μM 5-aza-CdR, a
DNA methylation inhibitor, for 72 hours, substantially
(>2.0-fold) and significantly (P < 0.05) increased the ex-
pression of miR-370 in both HL60 and K562 cells
(Figure 3A) and decreased cell proliferation (Figure 3D)
(control vs CdR: HL60: 24 ± 4 vs 7 ± 2, p < 0.01; K562:
152 ± 5 vs 78 ± 5, p < 0.001).
Identification of FoxM1 as a target for miR-370
To further elucidate the mechanism by which miR-370
affected cellular senescence and proliferation, we next
screened for potential targets of miR-370 using four tar-
get prediction programs with different algorithms:
DIANA-MicroT [23], TargetScan [24], Miranda [25] and
PicTar [26]. All potential targets predicted by more than
one of these programs were identified. We selected the
forkhead box M1 (FoxM1) for further study because of
its well-characterized role in tumor biology. The FoxM1
gene has a 249-bp 30UTR region that presents a 7-mer
binding site for miR-370 (Figure 4A).
First, we made the luciferase reporter constructs con-
taining the miR-370 recognition sequence from the 30-
UTR of FoxM1 inserted downstream of the luciferase
gene. Transfection with miR-370 precursor decreased re-
porter activity in K562 cells (Figure 4B), which strongly
indicates that FoxM1 is a target for miR-370. Next, the
studies were repeated with random mutations in the rec-
ognition sequence (Figure 4A), which resulted in aboli-
tion of the reporter activation by miR-370 precursor
(Figure 4B). Finally, we assessed the effect of miR-370
expression on FoxM1 expression. Transfection of HL60
and K562 cells with miR-370 precursor resulted in lower
expression of FoxM1 after 48 hours (Figure 4C-D). Con-
comitant with decreased FoxM1 expression, there was
reduction of its downstream target c-myc and skp2(Figure 4C-D). There was a >2-fold increase in expres-
sion of FoxM1 in HL60 and K562 cells after transfection
of miR370 inhibitor plasimids (Figure 4E). 5-aza-CdR
significantly reduced the expression of FoxM1 in both
HL60 and K562 cells (Figure 3 B-C). These changes
were similar to those observed with miR-370 overex-
pression. Taken together, FoxM1 is a target of miR-370.
Overexpression of FoxM1 in de novo AML patients
FoxM1, a master regulator of mitotic gene expression, is
required for cell proliferation and its inhibition leads to
reduction in anchor-independent growth and tumori-
genesis of cancer cells [27]. As we have verified that
FoxM1 is a target for miR-370, we then sought to probe
its role in AML. The tumor specimens from forty-eight
de novo AML patients and forty AML patients in 1st
CR and twenty-one healthy controls were analyzed for
FoxM1 mRNA expression using qRT-PCR. Patient char-
acteristics are described in Table 1. The FoxM1 tran-
script level in AML patients was found 21.47-fold higher
than that in controls, while following acquisition of CR
in the induction chemotherapy, FoxM1 expression level
reduced to 1.75 fold of controls. (Figure 5 A, C), which
was negatively correlated with miR-370 levels. There was
a highly significant difference in FoxM1 expression be-
tween AML samples, CR samples and healthy controls
(qRT-PCR, One-Way ANOVA, p < 0.01). In six patients,
BM samples were available both at diagnosis time prior
to treatment and after a complete remission and we
found a higher FoxM1 level at diagnosis while a signifi-
cant decrease in FoxM1 expression after CR except one
sample (Figure 5B). There was no clear association be-
tween the presence of FoxM1 mRNA and age, gender,
tumor burden or FAB subtypes (data not shown). More-
over, BM materials from 8 de novo AML patients, 8
patients in 1st CR and 5 healthy controls randomly
chosen from our AML patient pool were used to deter-
mine the mRNA expression level of c-Myc, hTERT,
p27kip1 and skp2, all of which were the target genes of
FoxM1, using real-time PCR method. We found that the
transcript levels of c-Myc, hTERT and skp2 in AML
patients were respectively 9.64, 3.76 and 3.14-fold higher
than those in controls, while following acquisition of
CR, all of them reduced almost to the same levels of
Figure 3 Expression of miR-370 in AML cells (HL60 and K562) and the effect of 5-aza-2’deoxycytidine (5-Aza-CdR). AML cells were plated
in 6-well plates, treated with 5 μM 5-Aza-CdR or PBS and harvested after 72 hours. The expression of mature miR-370 was assessed using
real-time PCR. (A) 5-aza-CdR increases the relative expression of miR-370 in AML cells. Data represent mean ± s.e. from three separate
determinations. *p < 0.05 compared with respective controls. (B) 5-aza-CdR decreases the relative mRNA level of FoxM1 in AML cells.
*p < 0.05. (C) 5-aza-CdR decreases the protein level of FoxM1 in AML cells. (D) Diminished foci formation of 5-aza-CdR treated AML cells.
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in AML patients is only 40% of that in controls, while
restored after CR (Additional file 2).
Defective foci formation by depletion of FoxM1 in AML
cell lines
Then, we employed the FoxM1-specific siRNA to knock
down FoxM1 expression in AML cell lines and the cells
were then assessed for their clonogenic capacity. Effi-
cient silence of FoxM1 expression in these cells was
verified using qRT-PCR and Western blot analyses
(Figure 5 D-E). Compared to the control cells, the
FoxM1-knocked down cells exhibited significantly
diminished foci formation (Figure 5F) (Controls vs
FoxM1 siRNA: HL60: 19 ± 3 vs 11 ± 2, p < 0.05; K562:
33 ± 5 vs 5 ± 2, p = 0.001). Following FoxM1 depletion,
its target genes c-myc, skp2 and hTERT were also down-regulated and coupled with the accumulation of the
CDK inhibitor p27kip1 (Figure 5 D-E).
Collectively, the FoxM1 gene is aberrantly activated in
AML and is required for sustained proliferation of the
cancer cells.
Discussion
In the present study, we explored the expression and
role of miR-370 in AML. Our findings show a down-
regulation of miR-370 in blasts from patients with de
novo AML. Moreover, we identified FoxM1 as a target
for miR-370 and restored expression of miR-370 reduced
the level of FoxM1. In hematological malignancies a link
with miRNA was initially described in chronic lympho-
cytic leukemia (CLL) by Calin et al. [28]. A cluster of
two miRNAs, miR-15a, and miR-16, was found to be
located within the deleted region at 13q14, and down-
Figure 4 Identification of FoxM1 as a target of miR-370. (A) Predicted site of miR-370 in the FoxM1 3’ UTR mRNA. (B) Luciferase activities
were determined at 24 hours and were normalized by Renilla luciferase activity. K562 cells were plated in 24-well plates, and then transfected
with 0.05 μg of a Renilla luciferase expression construct pRL-TK and 0.5 μg of the pGL3-FoxM1-wt-luc or pGL3-FoxM1-mut-luc firefly luciferase
expression construct, along with either miR-370 precursor or control precursor. Luciferase assays were performed after 24 hours using the dual
luciferase reporter assay system. The expression of firefly luciferase activity was normalized to that of renilla luciferase activity for each sample. A
decrease in relative firefly luciferase activity in the presence of miR-370 indicates the presence of a miR-370 modulated target sequence in the 3’-
UTR of FoxM1. Data represents mean ± s.e. from three separate experiments. *P < 0.05. (C) and (D) The expression of FoxM1 and downstream
genes were regulated by miR-370 overexpression at both transcription level and translation level. Western blots were performed and sequentially
probed with antibodies against FoxM1, c-Myc and p27kip1, β-actin was a loading control. Efficient miR-370 overexpression was verified in Figure 2
(A). (E) Increase in FoxM1 protein level after anti-miR-370 treatment. Efficient miR-370 depletion was verified in Figure 2 (B).
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miR-15a and miR-16-1 down-regulation contribute to
malignant transformation by up-regulating BCL2 [29].
Recently, involvement of miRNA in AML has been
documented identifying that miRNA expression profiles
are AML subtype-specific and suggesting a pathogenetic
role of miRNA in AML. For example, Mi and colleagues
[30] showed distinct miRNA signatures between acute
lymphoblastic leukemias (ALLs) and AMLs. In that
study, patients with AML could be separated from thosewith ALL on the basis of 21 up-regulated and 6 down-
regulated miRNAs, among which four of them (let-7b,
miR-128a, miR-128b and miR-223) were the most dis-
criminatory [31]. According to Amanda Dixon-McIver,
compared with other major cytogenetic subgroups of
AML, APLs bearing the t(15;17) translocation were
characterised by the up regulation of 7 miRNAs tran-
scribed from genes located at the 14q32 region. The set
includes miR-127, miR-154, miR-154*, miR-299, miR-
323, miR-368, and miR-370. Two other groups reported
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patients with FLT3-ITD, suggesting that this miRNA
contributes to the highly proliferative phenotype of this
molecular subset of AML [31-33]. In the present study,
we haven’t got the conclusion that the expression level
of miR-370 is with AML subtype-specificity, which may
be due to the limited number of primary AML patients
enrolled in our study.
DNA methylation is an epigenetic modification that
can regulate gene expression. Aberrant DNA methyla-
tion has been implicated in many cancers [21]. miR-370
and many other miRNAs are organised in clusters to-
gether on chromosome 14q32 [34]. This miRNA cluster
acts as imprinted non-coding RNA (ncRNA) genes,
which are mono-allelically expressed in a parent-of-
origin manner (their expression is restricted to either
the maternal or the paternal allele). Interestingly, as for
this miRNA cluster, which is of maternal origin, its
imprinted expression is regulated by an intergenic differ-
entially methylated region (DMR) located ~ 200 kb up-
stream from the miRNA cluster [24]. Hypermethylation
of DMR causes silence of this miRNA cluster, including
miR-370. It has been suggested that miRNAs in this re-
gion act as tumour repressor genes and that changes in
the methylation status of their promoters could triggercancer development [35]. For instance, miR-127 has
been shown to be down regulated or silenced in cancer
cells, whose expression is correlated with the methyla-
tion and acetylation status of its promoter. Inhibition of
methylation and histone deacetylation in these cancer
cells causes over expression of miR-127 and related
down regulation of the target BCL6, a bona fide pro-
tooncogene [36]. We hypothesize that miR-370 also
acts as a tumor suppressor in AML, as in papillary
thyroid carcinoma, colorectal cancer and malignant
cholangiocytes. The comparison of the leukemia sam-
ples with healthy controls highlighted the differential
expression of miR-370. Following the treatment with
5-aza-20-deoxycytidine, there is a significant enrich-
ment for miR-370 in AML cell lines, which indicated
that hypermethylation may contribute to reduction of
miR-370.
Cancer therapy has traditionally relied on cytotoxic
treatment strategies on the assumption that complete
cellular destruction of tumors optimizes the potential for
patient survival. Although these approaches produce
complete cell death within a tumor, they also can cause
severe side effects in patients [37]. Recently, a promising
approach to preventing continued tumor growth is
therapy-induced senescence (TIS) [38]. Senescent cells
remain viable and metabolically active but are perman-
ently growth arrested [39]. Evidence has recently accu-
mulated that cellular senescence is a potent barrier to
cancer development. Our results indeed demonstrated
that senescence occurred in most of AML cells treated
with miR-370 overexpressing plasmid, which was con-
comitant with their diminished clonogenic capacity.
Given a critical role for senescence induction in tumor
suppression and therapeutic efficacy of cancer treat-
ment, the present findings have important biological
and clinical implications. All these results suggest that
downregulation of miR-370 may be another mechanism
involved in the pathology of AML and therefore, could
be used as a diagnostic marker and therapeutic target
in AML.
We have also analyzed the correlation between miR-
370 expression and FoxM1 mRNA expression in 48 de
novo AML samples. Consistent with the cell line data,
FoxM1 was enriched in the primary blasts mRNAs that
inversely correlated to miR-370 expression levels. This
result was also observed at the protein level in a few pri-
mary AML samples. However, further studies using large
numbers of primary AML samples will be needed to
confirm this interaction.
Conclusion
We demonstrate that miR-370 is a tumor suppressive
factor by targeting multiple critical oncogenic pathways.
Restoring miR-370 expression downmodulates FoxM1,
Figure 5 Overexpression of FoxM1 in de novo AML patients and defective foci formation induced by depletion of FoxM1 in AML cell
lines. (A) and (C) Expression of FoxM1 mRNA and protein in de novo AML patients, AML patients of 1st CR and controls, were determined using
qRT-PCR and Western blot respectively. (B) Decrease of FoxM1 expression in six patients after complete remission achievement in induction
chemotherapy. (D) and (E) FoxM1 depletion triggers concomitant down-regulation of c-myc, hTERT and skp2 coupled with the accumulation of
the CDK inhibitor p27kip1 in AML cells. The cells were transfected with either control or FoxM1 siRNA and harvested after 72 hours. qRT-PCR and
western blot were applied to detect mRNA and protein levels, respectively. (F) Diminished foci formation of FoxM1-depleted AML cells. The cells
were first treated as above and the efficient FoxM1 knock down was verified in (D) and (E).
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cells, thereby suggesting miRNA-based therapy as a
novel approach to increase response in AML.
Materials and methods
Patients and bone marrow samples
Forty-eight newly diagnosed AML patients (31 male and
17 female; median age at diagnosis 41; range 14–74),
forty AML patients in 1st complete remission (CR) and
twenty-one healthy controls were enrolled in this study.
Diagnosis of AML was established according to clinicalpresentation and morphologic criteria of the French-
American-British (FAB) Classification. The study was
approved by the local ethics committee. Patients’ BM
samples were collected between April 2008 and Septem-
ber 2011 at the Department of Hematology, Qilu Hos-
pital, Shandong University, Jinan, China. Mononuclear
cells were isolated using Ficoll-Hypaque density gradient
centrifugation, and then stored at −80°C until use. All
patients and healthy controls were tested for miR-370
and FoxM1 mRNA levels in their BM cells. Among
those AML patients, six were analyzed for miR-370 and
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diagnosis and complete remission.
Cell lines and culture conditions
Human AML cell lines HL60 and K562 were cultured at
37°C, 95% air, 5% CO2 in RPMI 1640 containing 10%
heat-inactivated fetal bovine serum (FBS; Gibco,
Carlsbad, CA, USA), 100 μg/mL penicillin, and 50 μg/mL
streptomycin. To assess 5-aza-CdR (Sigma, Santa Clara,
CA, USA) effects, cells were grown on 6-well plates, trea-
ted with 5 μM 5-aza-CdR or cold phosphate-buffered sa-
line (PBS) controls for 72 h at 37°C, and then harvested
for isolation of total mRNA or protein.
RNA extraction and quantitative real-time PCR
Total cellular RNA in BM samples and in cells with dif-
ferent treatments was extracted using the Trizol (Invitro-
gen, Carlsbad, CA, USA) according to the manufacturer’s
protocol. cDNA was synthesized using random primers
(N6) (Fermentas, St. Leon-Rot, Germany) and MMLV re-
verse transcriptase. The PCR primers used in the study
were as follows: sequences specific for FoxM1 mRNA: 50-






50-CGGAAGAGTGTCTGGAGCAA-30 (Forward) and 50-
GGATGAAGCGGAGTCTGGA-30 (Reverse); c-MYC: 50-
TACCCTCTCAACGACAGCAGCTCGCCCAACTCCT-30
(Forward) and 50-TCTTGACATTCTCCTCGGTGTCC
GAGGACCT-30 (Reverse). The above primer pairs cross
intron/exon boundaries; thus, the resultant PCR products
do not represent genomic DNA contamination. β-actin
expression was used as a control for RNA loading and RT
efficiency and amplified. Quantitative real-time polymerase
chain reaction (qRT-PCR) was carried out in an ABI7000
sequence detector (Applied Biosystems, Foster City, CA,
USA).
TaqMan qRT-PCR miRNA analysis
Quantification of mature miRNAs was performed using
qRT-PCR with the TaqMan miRNA assay kit (Applied
Biosystems, Foster City, CA, USA) according to manufac-
turer’s instruction. Briefly, 10 ng of total RNA was re-
verse-transcribed (RT) with specific primers, subsequently
1.5 μL of RT product was used as template for real-time
PCR. All real-time experiments were performed in tripli-
cate. Data were normalized by the expression of small
nuclear RNA (snRNA) U6 and expressed either as rela-
tive expression (2-ΔCt) or as fold change relative to con-
trol (2-ΔΔCt).Western blot
Total cellular proteins were extracted from cultured cells
or BM samples. Proteins were resolved by SDS-PAGE
and transferred to a nitrocellulose membrane. The mem-
branes were probed with the specific antibodies against
FoxM1, p27, c-MYC (Santa Cruz Biotechnologies, Santa
Cruz, CA, USA), followed by anti-mouse or rabbit horse-
radish peroxidase–conjugated IgG and developed with
the enhanced chemiluminescence method (ECL). β-actin
served as a loading control.
miR-expressing and miR-inhibiting plasmids
To generate the miR-expressing pSilencer3.1-H1 neo
vector, a fragment of 212 base pairs (bp) corresponding
to the desired miRNA and the surrounding sequences
was amplified from human genomic sequence, adding a
BamHI site and a HindIII site to the 50 and 30 ends re-
spectively, using the polymerase chain reaction (PCR)
with primers sense: 50 AAGGGATCCTACTTGAGG
GATGGGCGATA 30 and antisense 50 TCAAAGCTTC
CCGAGCTCTGGTGTTAGAC 30. We included a large
portion of miRNA surrounding sequence in the attempt
to allow correct processing of the miRNA to its mature
form and to induce overexpression while preserving a
physiologic mechanism of miRNA production. miR-370
inhibitor sequences were synthesized as DNA oligonu-
cleotides; after annealing, were sticking ended and sub-
cloned into a pSuper vector.
Transfection
Cells were incubated in 6-well plates (3.0× 105/well and
1.0× 105/well, respectively) overnight and were then
transfected with plasmid or siRNA using Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s protocol. Chemical modified Stealth small
interfering RNA (siRNA) targeting FoxM1 and control
siRNA were bought from Invitrogen. The sequence for
the FoxM1 siRNA was 50-GACAACUGUCAAGUGUAC
CACUCUU-30.
Soft agar colony formation assay
HL60 and K562 cells were resuspended in DMEM (Gibco,
Carlsbad, CA, USA) containing 20% heat-inactivated fetal
bovine serum (FBS; Gibco, Carlsbad, CA, USA) with equal
amount of either 0.3% agar (HL60 cells) or 0.5% agar
(K562 cells), and plated in 6-well plates at 5,000 per well
on top of a 2 mL precast semisolid 1% agar underlayer as
described previously [40]. The number of colonies with
more than 50 cells was counted after two weeks.
Senescence-associated β-Galactosidase
(SA -β-Gal) staining
SA -β-Gal staining was done as described [19,41]. Briefly,
the cells grown in 6-well plates were transfected with
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rinsed with PBS once, fixed in 3% of formaldehyde for
15 min, and incubated with freshly prepared SA -β-Gal
staining solution at 37°C overnight.
Luciferase reporter vector
The precursor to miR-370 was synthesized and cloned in
pSilencer. Firefly luciferase reporter vectors with the intact
putative miR-370 recognition sequence from the 30-UTR
of FoxM1 (pGL3-FoxM1-wt-30-UTR) or with random
mutations (pGL3-FoxM1-mut-30-UTR) cloned down-
stream of the firefly luciferase gene were constructed.
Wild-type and mutant inserts were confirmed by sequen-
cing. For the 30UTR-luciferase assays, cells were co-
transfected with 0.5 μg pGL3-FoxM1-wt or mut-30-UTR
construct, 4 μg of pSilencer or pSilencer-miR and 0.05 μg
pRL-TK Renilla luciferase expression construct using Lipo-
fectamine 2000. Luciferase assays were performed 24 h
after transfection using the Dual Luciferase Reporter Assay
system (Promega, Madison, Wisconsin, USA).
Statistical analyses
The difference in miR-370 and FoxM1 mRNA expres-
sion among different patient groups as detected using
qRT-PCR was analyzed using One-Way ANOVA. The
comparison of foci numbers, β-Gal-positive cells, lucifer-
ase activity and miR-370, FoxM1, c-myc, hTERT, p27,
skp2 mRNA expression after different treatments was
made using a Student’s t-test. All the tests were two-
tailed and computed using SPSS11.5 software. Results
are depicted as the mean ± standard error of the mean.
P values < 0.05 were defined as statistical significance.
Additional files
Additional file 1: Proliferation curve of HL60 cell line (A) and K562
cell line (B) after transfection with miR-370-expressing plasmid or
the control pSilencer vector. 1 × 105/ml cells were plated in 6-well
plates just before the transfection. The number of viable cells was
counted at 24 h and 48 h points using trypan blue. Data represents
mean ± s.e. from three separate experiments. **p < 0.01 Student’s t-test.
Additional file 2: c-Myc, hTERT, p27kip1 and skp2 expression by
qRT-PCR in 8 de novo AML patients, 8 AML patients of 1st CR and
5 healthy controls. The transcript levels of c-Myc, hTERT and skp2 in AML
patients were found respectively 9.64, 3.76 and 3.14-fold higher than
those in controls, while following acquisition of CR in the induction
chemotherapy, all of them reduced almost to the same levels of controls.
On the contrary, the expression level of p27kip1 in AML patients is only
40% of that in controls, while restored after CR. *p < 0.05 One-Way
ANOVA.
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